SWAG SSG Skin Cancer Meeting Clinical Research Network West of England SWAG SSG Skin Cancer Meeting Tuesday 16th May 2017 Research Report

Clinical Research Network & Cancer Services West ofEngland SWAG - Somerset Wiltshire Avon & Gloucestershire South West Children’s Cancer & Leukaemia Research Network

NIHR CRN High Level Objectives 2016-17 Increase number of participants into NIHR CRN portfolio studies 650,000 in England 21,905 in West of England Increase the number of studies that deliver to time and target Target 80% Increase number of commercial studies delivered through network Reduce NHS study set up times Reduce time taken to recruit first participant

NIHR CRN Objectives for cancer 2016-17 Recruit 20% of cancer incidence West of England 1,909 Recruit 7.5% of cancer incidence into interventional studies 716 Include challenging studies Cancer surgery – 4 recruits per 100,000 population Radiotherapy – 6 recruits per 100,000 population Rare cancers (<6 per 100,000) – 12 recruits per 100,000 population Children & young people – 3 per 100,000 population Teenagers & young adults – record number of 16-25 year olds participating in research

Recruitment to Time and Target – Open Studies in May 2017

Cancer specialty objective for 2017-18 Number of LCRNs achieving on-target recruitment into at least 8 of the 13 Cancer subspecialties, where "on-target" means either improving recruitment by 10% from 2016/17 or meeting the following recruitment targets per 100,000 population served:  a) Brain & CNS: 0.2; b) Breast: 8; c) Colorectal: 3; d) Paediatrics: 3; e) Gynae: 3; f) Head & Neck: 1; g) Haematology: 7; h) Lung: 4; i) Sarcoma: 0.1; j) Skin: 0.2; k) Supportive & Palliative Care and Psychosocial Oncology & Survivorship: 3; l) Upper GI: 3; m) Urology: 8.

2016/17 YTD performance against 2017/18 Cancer specialty target

Open studies – Skin CPMS ID Study Title Project Status Site Planned end date PI 18162 MelMarT - A Phase III, multicentre, multinational randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma.  Suspended North Bristol NHS Trust 01/01/2016 Wilson , Dr Ewan 19639 The PERM Study - Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma Open University Hospitals Bristol NHS Foundation Trust 01/11/2018 Herbert, Dr Chris 32773 TRILOGY – A Phase III Study of Atezolizumab plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma. 31/08/2018

Studies in set up CPMS ID Study Title Site PI Summary 20444 RATIONAL MCC - North Bristol NHS Trust Challapalli, Dr Amarnath A randomised phase III multi-centre trial comparing radical surgery and radical radiotherapy as first definitive treatment for primary MCC with an observational study for patients ineligible for the randomised trial.

Useful links https://www.crn.nihr.ac.uk/ National and local network information including training programmes templates, tools, contacts, videos etc https://odp.nihr.ac.uk/ http:/ Open data platform. Look at performance across whole CRN including all specialty areas http://csg.ncri.org.uk/portfolio/portfolio-maps/ View current national portfolio of open, closed and ‘in set up’ cancer studies https://www.ukctg.nihr.ac.uk/ See where a study is open across the country http://public-odp.nihr.ac.uk/  Search for a study to fit criteria. Good for horizon scanning, eligibility criteria

Contacts Research Delivery Manager – david.rea@nihr.ac.uk Cancer portfolio facilitator – sarah.west@nihr.ac.uk Skin research lead – christopher.herbert@uhbristol.nhs.uk

Current Issues with Cancer Research Gaps in the portfolio Clinical pressures with some trial treatments Pharmacy capacity issues Extra time for administration of infusions Extra length of treatment courses Clinic space to see patients Affordability to the NHS of the drugs we are researching What should our regional portfolio look like? Should we consider the whole region population when forecasting for trials? Should we encourage more cross referral of patients for studies? Should we select studies that will be more useful to the NHS?